Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Summary

This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect).

Conditions

• Prolymphocytic Leukemia
• Recurrent Adult Hodgkin Lymphoma
• Recurrent Childhood Hodgkin Lymphoma
• Recurrent Childhood Non-Hodgkin Lymphoma
• Recurrent Chronic Lymphocytic Leukemia
• Recurrent Non-Hodgkin Lymphoma
• Recurrent Small Lymphocytic Lymphoma
• Refractory Childhood Hodgkin Lymphoma
• Refractory Chronic Lymphocytic Leukemia
• Refractory Hodgkin Lymphoma
• Refractory Non-Hodgkin Lymphoma
• Refractory Small Lymphocytic Lymphoma
• T-Cell Chronic Lymphocytic Leukemia
• T-Cell Prolymphocytic Leukemia

Interventions

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous transplantation

PROCEDURE

Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation

Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation

DRUG

Carmustine

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Cyclosporine

Given PO

DRUG

Cytarabine

Given IV

DRUG

Etoposide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

DRUG

Mycophenolate Mofetil

Given PO

PROCEDURE

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic transplantation

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic transplantation

BIOLOGICAL

Therapeutic Autologous Lymphocytes

IV donor lymphocyte infusion

RADIATION

Total-Body Irradiation

Undergo radiotherapy

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Fred Hutchinson Cancer Center

  lead OTHER

Principal Investigators

• David Maloney · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1999-09-30

Primary Completion

2016-01-31

Completion

2018-10-31

Countries

• United States
• Germany

Study Locations